Literature DB >> 18952065

A new evaluation method for quantifying PI3K activity by HTRF assay.

Hironobu Sugita1, Shingo Dan, Dexin Kong, Akihiro Tomida, Takao Yamori.   

Abstract

PIK3CA, coding a catalytic subunit of PI3K p110alpha, is frequently mutated in cancer. In previous studies, p110alpha with hotspot mutations such as E545K and H1047R were shown to be gain-of-function mutations. However, quantitative evaluation of these mutants was not well established. Recently, a new method for measuring PI3K activity using homogeneous time-resolved fluorescence (HTRF) has been developed. Using this method, we constructed a quantitative evaluation system for PI3K activity. Serial dilutions of standard PIP3 were subjected to the PI3K-HTRF assay in order to establish a regression line for calibration. The recombinant FLAG-tagged p110alpha proteins were engineered together with a regulatory subunit p85alpha in human embryonic kidney 293T cells. Anti-FLAG-Ig immunoprecipitates were then subjected to the assay, which enabled us to quantitatively evaluate the activities of hotspot mutants of p110alpha. We believe this method will also be applicable to the evaluation of p110alpha having uncharacterized mutations found in cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952065     DOI: 10.1016/j.bbrc.2008.10.083

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.

Authors:  Dexin Kong; Takao Yamori; Kanami Yamazaki; Shingo Dan
Journal:  Invest New Drugs       Date:  2014-08-26       Impact factor: 3.850

Review 2.  Phosphatidylinositol 3-kinase: the oncoprotein.

Authors:  Peter K Vogt; Jonathan R Hart; Marco Gymnopoulos; Hao Jiang; Sohye Kang; Andreas G Bader; Li Zhao; Adam Denley
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.

Authors:  Mitsutaka Kadota; Misako Sato; Beverly Duncan; Akira Ooshima; Howard H Yang; Natacha Diaz-Meyer; Sheryl Gere; Shun-Ichiro Kageyama; Junya Fukuoka; Takuya Nagata; Kazuhiro Tsukada; Barbara K Dunn; Lalage M Wakefield; Maxwell P Lee
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

4.  Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.

Authors:  Nadine Dannemann; Jonathan Ross Hart; Lynn Ueno; Peter K Vogt
Journal:  Int J Cancer       Date:  2010-07-01       Impact factor: 7.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.